BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences:
TD Cowen Virtual Immunology & Inflammation Summit
Fireside Chat: Wednesday, November 12, 2025, at 2:30pm ET
8th Annual Evercore Healthcare Conference
Fireside Chat: Tuesday, December 2, 2025, 3:00pm ET
Location: Miami, FL
A live webcast and archived replay of the fireside chats will be available on the investors section of www.vorbio.com.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Media & Investor Contacts:
Carl Mauch
This email address is being protected from spambots. You need JavaScript enabled to view it.
Sarah Spencer
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$18.70 |
| Daily Change: | -0.27 -1.42 |
| Daily Volume: | 327,216 |
| Market Cap: | US$128.100M |
November 08, 2025 October 22, 2025 October 17, 2025 October 16, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
